VERAXA starts cell line work for BiTAC T-cell engager
- VERAXA Biotech (NASDAQ:VRXA) initiated cell line development for its lead BiTAC-TCE program.
- The company is working with ATUM to use Leap-In Transposase technology for stable clonal cell lines.
- The step supports IND/CTA-enabling activities for future clinical development.
VERAXA Biotech (NASDAQ:VRXA) said it has begun cell line development for its lead BiTAC T-cell engager (BiTAC-TCE) candidate.
The company is partnering with ATUM to apply its Leap-In Transposase technology in developing stable clonal cell lines.
VERAXA said the process is a key step toward IND and CTA-enabling activities required before human clinical trials.
The cell line development is intended to support future manufacturing and clinical production of the BiTAC-TCE program.
BiTAC-TCE programs are designed to engage T-cells to target disease-related cells, and stable cell line development is a standard early-stage manufacturing milestone.
VERAXA said the collaboration supports advancement of its most developed BiTAC-TCE candidate toward clinical readiness.
Frequently asked questions
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue